Rangering i aksjer
#15446
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops... BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Handel BioAge Labs Inc. (BIOA)
Pris BIOA pris med markedsverdi på B
Markedsverdi av BioAge Labs Inc.(BIOA)
Markedsverdi: $355.41M
Per September 2026 har BioAge Labs Inc. en markedsverdi på $355.41M. Dette gjør BioAge Labs Inc. til det 15446th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for BioAge Labs Inc. fra 2024 til 2026
BIOA sammenlignet med topp 5 mest populære stocks
| Pris på BIOA |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.226T
|
+1,470,351.76%
|
|
|
|
|
$4.713T
|
+1,325,889.19%
|
|
|
|
|
$4.034T
|
+1,134,843.41%
|
|
|
|
|
$3.738T
|
+1,051,558.11%
|
|
|
|
|
$2.744T
|
+772,071.50%
|
